Prostate Cancer Therapeutics Market - Global Forecast 2025-2030

The Prostate Cancer Therapeutics Market size was estimated at USD 10.62 billion in 2024 and expected to reach USD 11.32 billion in 2025, at a CAGR 6.34% to reach USD 15.37 billion by 2030.

The global burden of prostate cancer underscores a pressing need for innovative therapies. With an estimated 1.5 million new cases diagnosed and nearly 400,000 deaths worldwide in 2022, this disease ranks second in incidence and fifth in mortality among men globally. Despite advances in early detection and localized treatments, metastatic disease remains lethal for many patients, prompting ongoing efforts to develop novel systemic therapies. Moreover, disparities in incidence and outcomes across regions highlight the complexity of addressing prostate cancer on a global scale, as high‐income North American and European markets drive much of the research investment while emerging markets face evolving diagnostic capabilities.

Over the past two decades, prostate cancer therapeutics have evolved from general cytotoxic regimens toward more targeted approaches. Initial reliance on taxane‐based chemotherapy established a foundation for survival benefits in metastatic castration-resistant disease, but concerns about systemic toxicity spurred the search for more selective treatments. Concurrently, radiopharmaceuticals emerged, leveraging the radiosensitivity of prostate tumors to deliver alpha or beta emitters directly to malignant cells, minimizing collateral damage to healthy tissue. These advancements set the stage for next‐generation modalities that combine precision targeting with novel mechanisms of action.

Recent breakthroughs in radiopharmaceutical therapies have redefined treatment paradigms for advanced prostate cancer. Novartis’ lutetium-177 PSMA-617 (Pluvicto) achieved first-in-class status by harnessing a selective ligand to deliver beta radiation directly to PSMA-expressing tumor cells, demonstrating a marked survival advantage with minimal off-target effects. Meanwhile, pioneering efforts in alpha-emitter research, particularly involving actinium-225, promise higher linear energy transfer and potent double-strand DNA breaks in cancer cells. However, global supply shortages of actinium-225 present a significant bottleneck, driving collaborations between major pharmaceutical companies to secure reliable isotope sources.

Concurrently, the integration of precision medicine through PARP inhibitors and immune modulators has accelerated progress. The AMPLITUDE trial notably extended progression-free survival by adding niraparib to abiraterone acetate in HRR-mutated patients, reflecting a 37 percent risk reduction in radiographic progression. Innovative combination immunotherapies, such as the SYNC-T platform integrating anti-CTLA-4, anti-PD-1, CD40 agonists, and TLR9 agonists, achieved an 87 percent overall response rate with durable control and manageable safety in a phase 1 cohort of mCRPC patients, signaling a new frontier for multimodal immune strategies.

In April 2025, the United States instituted a broad 10 percent tariff on all imported goods, including pharmaceutical ingredients, under Section 232, aiming to stimulate domestic manufacturing and reduce supply vulnerabilities. Additionally, a 25 percent duty on active pharmaceutical ingredients sourced from China and India was imposed, directly affecting the backbone components for chemotherapy agents and hormone therapies, while a 15 percent tariff on medical packaging and laboratory equipment disrupted downstream manufacturing timelines for biologics and radiopharmaceutical preparations.

These trade measures have exerted pronounced pressure on the prostate cancer therapeutics supply chain. Oncology APIs, which accounted for over $26 billion in trade value in 2023, are now subject to higher import costs that could be passed through to treatment centers and patients. Radiopharmaceutical developers face added hurdles, as the specialized machinery and isotopes-already constrained by global actinium shortages-now incur elevated tariffs that inflate production costs and threaten to delay trial enrollments and commercial launches.

Prostate cancer therapeutics can be dissected through a multi-dimensional lens that spans therapeutic mechanism, therapy line, formulation, distribution channel, and end user. Mechanism-based segmentation encompasses classic cytotoxic chemotherapy divided into platinum compounds and taxanes, alongside hormone therapies that include antiandrogens, CYP17 inhibitors, GnRH agonists, and GnRH antagonists. Immunotherapy’s burgeoning role is further differentiated into cancer vaccines, cell therapies, and checkpoint inhibitors, whereas radiopharmaceuticals harness alpha and beta emitters. Targeted therapies round out the spectrum with monoclonal antibodies, PARP inhibitors, and tyrosine kinase inhibitors.

Complementing mechanism-level insights, the therapy line segmentation distinguishes first-line interventions from second-line regimens and third-line and beyond scenarios, reflecting the sequential nature of treatment decisions in mCRPC. Formulation considerations span injectable versus oral dosing, which influences administration settings and patient adherence. Distribution channels encompass hospital pharmacies, online platforms, and retail outlets, each with unique regulatory and logistical attributes. Finally, end users, from comprehensive cancer centers and specialty clinics to homecare providers and hospital systems, define the clinical environments where these therapies are deployed.

The Americas remain a pivotal driver of innovation in prostate cancer therapeutics. The United States and Canada lead in clinical trial volume and R&D investment, supported by favorable reimbursement pathways and robust oncology infrastructure. High incidence rates-among the highest globally at approximately 73.5 per 100,000 men-sustain demand for advanced treatments across hormone, radiopharmaceutical, and targeted therapy classes.

Within Europe, Middle East, and Africa (EMEA), regulatory harmonization under European agencies and national health technology assessment frameworks shape market access. Pricing pressures and volume-based procurement in parts of Europe contrast with expanding private-sector care models in the Middle East. In Asia-Pacific, diverse market dynamics span mature markets like Japan-where localized clinical data guide first-line approvals-to emerging markets in China and India, where rising incidence and improving healthcare infrastructure are catalyzing adoption of novel modalities.

Novartis has emerged as a frontrunner in radioligand therapy with the commercial success of lutetium-177 PSMA-617, achieving breakthrough status in 2022 and catalyzing further investments in actinium-225 programs such as PSMA-R2, currently in Phase I/II trials for mHSPC and mCRPC. Bristol Myers Squibb’s acquisition of RayzeBio in late 2023 brought a differentiated actinium-based radiopharmaceutical platform into its oncology portfolio, advancing RYZ101 in neuroendocrine tumor indications and strengthening its capacity to support prostate cancer imaging and therapeutic licensing deals.

Janssen’s AKEEGA® combination of niraparib and abiraterone acetate represents a strategic expansion of PARP inhibitor utility into BRCA-mutated mCRPC, securing FDA approval in 2023 and EC authorization in 2025 based on MAGNITUDE trial outcomes. Johnson & Johnson further validated this paradigm with the AMPLITUDE study demonstrating rPFS benefits in mCSPC, cementing the role of precision medicine and genomic testing in guiding first-line therapy decisions.

Industry leaders should prioritize diversification of supply chains to mitigate raw material constraints and tariff exposure. By forging strategic partnerships with isotope producers and localizing key manufacturing steps, organizations can enhance resilience against disruptions and protect critical clinical timelines. Furthermore, integrating advanced analytics to monitor trade policy developments and proactively adjust procurement strategies will be essential to contain costs and maintain profitability in a shifting regulatory landscape.

Investment in biomarker-driven clinical programs must remain a core focus, as demonstrated by the success of HRR-targeted PARP combinations and PSMA-directed radioligand therapies. Companies should employ adaptive trial designs that enable real-time stratification and seamless enrollment across global regions. Simultaneously, aligning commercial strategies with evolving reimbursement models-such as value-based pricing and indication-based contracts-will ensure sustainable access to high-impact treatments and reinforce payer confidence in long-term patient outcomes.

This report employs a dual approach of extensive secondary research and targeted primary investigations. Secondary data were collected from peer-reviewed journals, regulatory agency databases, clinical trial registries, and global epidemiology repositories to establish a robust understanding of therapeutic classes, regulatory frameworks, and market drivers. Primary insights were gathered through structured interviews with key opinion leaders, industry executives, and clinical trial investigators to validate emerging trends and capture real-time intelligence on supply chain dynamics.

Data triangulation ensured methodological rigor: quantitative inputs from trade and import data were cross-referenced with qualitative expert feedback to identify supply constraints and tariff impacts. Comparative analyses across regional databases and clinical registries illuminated geographic variations in adoption patterns. Finally, iterative validation workshops with stakeholder panels refined the actionable recommendations, ensuring they align with operational realities and strategic imperatives of leading biopharmaceutical organizations.

Through a synthesis of clinical advancements, policy shifts, and commercial imperatives, it is clear that prostate cancer therapeutics are entering a new era of precision and personalization. Radioligand therapies leveraging beta and alpha emitters have demonstrated transformative efficacy, while molecularly guided combinations of PARP inhibitors and androgen pathway agents have redefined survival expectations for biomarker-selected patients. Concurrently, evolving trade policies and supply chain challenges underscore the need for strategic agility and diversified sourcing.

Moving forward, stakeholders must balance innovation with access by aligning clinical development plans with emerging reimbursement paradigms and regulatory incentives. Embracing adaptive trial designs, real-world evidence generation, and value-based contracting models will enable sustainable growth and patient-centric outcomes. Ultimately, integrated strategies that address scientific, economic, and logistical dimensions will be pivotal to converting therapeutic breakthroughs into standard-of-care realities for men living with prostate cancer.

Contact Ketan Rohom to discuss how our comprehensive market research report on prostate cancer therapeutics can empower your strategic planning and competitive positioning. Gain exclusive access to in-depth analyses, expert insights, and actionable intelligence that will inform your product development, market entry, and investment decisions. Whether you are preparing for a new product launch, evaluating partnership opportunities, or refining your commercial strategy, this report provides the data and context you need to make informed choices. Reach out today to secure your copy, unlock privileged research privileges, and position your organization at the forefront of the rapidly evolving prostate cancer therapeutics landscape.